Combination therapy for asthma: Perspectives of the patient, provider, and payer

Disease Management and Health Outcomes

Volumn 14, Issue 6, 2006, Pages 353-368

  Farber, Harold J ^a   Glauber, James ^b  

^a KAISER PERMANENTE   (United States)

^b Neighborhood Health Plan   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHACHOLINE; MONTELUKAST; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TRIAMCINOLONE; ZAFIRLUKAST;

ASTHMA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; METERED DOSE INHALER; MONOTHERAPY; NEBULIZER; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; REVIEW; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT REFUSAL; TREATMENT RESPONSE;

EID: 33846267652     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200614060-00005     Document Type: Review

References (103)

1. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma. Update on selected topics 2002 [online]. Bethesda (MD): US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, 2003. NIH publication no. 02-5074. Available from URL: http://www.nhlbi.nih.gov/ guidelines/index.htm [Accessed 2006 Jun 20]
2. Farber HJ, Boyette M. Control your child's asthma: a breakthrough program for the treatment and management of childhood asthma. New York (NY): Henry Holt, 2001
3. Suissa S, Ernst P, Kezouh A, et al. Regular use of inhaled corticosteroids and the long term prevention of hospitalization for asthma. Thorax 2002 Oct; 57 (10): 880-4
4. Ernst P, Spitzer WO, Suissa S, et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA 1992; 268 (24): 3462-4
5. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000 Aug 3; 343 (5): 332-6
6. Sin DD, Man SF. Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma. Arch Intern Med 2002 Jul 22; 162 (14): 1591-5
7. Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001 Jun; 107 (6): 937-44
8. Global strategy for asthma management and prevention [online]. Bethesda (MD): National Institutes of Health, 1995. NIH publication no. 02-3659. Available from: URL: http://www.ginasthma.com [Accessed 2006 May 27]
9. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992 Feb 20; 326 (8): 501-6
10. Eisner MD, Lieu TA, Chi F, et al. Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma. Eur Respir J 2001 Feb; 17 (2): 233-40
11. Farber HJ, Chi FW, Capra A, et al. Use of asthma medication dispensing patterns to predict risk of adverse health outcomes: a study of Medicaid-insured children in managed care programs. Ann Allergy Asthma Immunol 2004 Mar; 92 (3): 319-28
12. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994 Jul 23; 344 (8917): 219-24
13. Evans DJ, Taylor DA, Zetterstrom O, et al. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997 Nov 13; 337 (20): 1412-8
14. Simons FE, Villa JR, Lee BW, et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr 2001 May; 138 (5): 694-8
15. Murray JJ, Church NL, Anderson WH, et al. Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc 1999; 20 (3): 173-80
16. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996 May; 153 (5): 1481-8
17. Juniper EF, Jenkins C, Price MJ, et al. Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma. Am J Respir Med 2002; 1 (6): 435-40
18. Jenkins C, Woolcock AJ, Saarelainen P, et al. Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma. Respir Med 2000 Jul; 94 (7): 715-23
19. Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003 Jul; 124 (1): 70-4
20. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol [published erratum appears in Chest 2006 May; 129 (5): 1393]. Chest 2006 Jan; 129 (1): 15-26
21. Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006 Jun 20; 144 (12): 904-12
22. Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting β2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001 May; 285 (20): 2583-93
23. Bensch G, Berger WE, Blokhin BM, et al. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol 2002 Aug; 89 (2): 180-90
24. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J 2002 Jan; 19 (1): 182-91
25. Yates DH, Kharitonov SA, Barnes PJ. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled β2-agonist [published erratum appears in Am J Respir Crit Care Med 1997 Apr; 155 (4): 1491]. Am J Respir Crit Care Med 1996 Dec; 154 (6 Pt 1): 1603-7
26. Kalra S, Swystun VA, Bhagat R, et al. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996 Apr; 109 (4): 953-6
27. Nelson HS, Nathan RA, Kalberg C, et al. Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids. MedGenMed 2001 Jul 5; 3 (4): 3
28. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast [published erratum appears in J Allergy Clin Immunol 2001 Apr; 107 (4): 614]. J Allergy Clin Immunol 2000 Dec; 106 (6): 1088-95
29. Ilowite J, Webb R, Friedman B, et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 2004 Jun; 92 (6): 641-8
30. Storms W, Chervinsky P, Ghannam AF, et al. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med 2004 Nov; 98 (11): 1051-62
31. Martinez FD. Safety of long-acting beta-agonists: an urgent need to clear the air. N Engl J Med 2005 Dec 22; 353 (25): 2637-9
32. Wooltorton E. Long acting β2-agonists in asthma: safety concerns. CMAJ 2005 Oct 25; 173 (9): 1030-1
33. Balkrishnan R, Nelsen LM, Kulkarni AS, et al. Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis. J Asthma 2005 Feb; 42 (1): 35-40
34. Palmqvist M, Arvidsson P, Beckman O, et al. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001; 14 (1): 29-34
35. Palmqvist M, Persson G, Lazer L, et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997 Nov; 10 (11): 2484-9
36. Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? [published erratum appears in Eur Respir J 2005 Dec; 26 (6): 1191]. Eur Respir J 2005 Nov; 26 (5): 819-28
37. Aalbers R, Backer V, Kava TTK, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004 Feb 1; 20 (2): 225-40
38. Leuppi JD, Salzberg M, Meyer L, et al. An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing. Swiss Med Wkly 2003 May 31; 133 (21-22): 302-9
39. Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006 Aug 26; 368 (9537): 744-53
40. Pedersen S. Budesonide plus formoterol for reliever therapy in asthma. Lancet 2006 Aug 26; 368 (9537): 707-8
41. FitzGerald JM, Boulet LP, Follows RM. The CONCEPT Trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther 2005 Apr; 27 (4): 393-406
42. Ringdal N, Chuchalin A, Chovan L, et al. Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide™ (50/250 microg bd Diskus™ vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler™) in patients with moderate-to-severe asthma. Respir Med 2002 Nov; 96 (11): 851-61
43. Jat GC, Mathew JL, Singh M. Treatment with 400μg of inhaled budesonide vs 200μg of inhaled budesonide and oral montelukast in children with moderate persistent asthma: randomized controlled trial. Ann Allergy Asthma Immunol 2006; 97: 397-401
44. Deykin A, Wechsler ME, Boushey HA, et al. Combination therapy with a long-acting (beta)-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med. Epub 2006 Sep 14
45. Ilowite J, Webb R, Friedman B, et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 2004 Jun; 92 (6): 641-8
46. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003 Oct 18; 327 (7420): 891
47. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000 Dec; 106 (6): 1088-95
48. Boushey HA, Sorkness CA, King TS, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005 Apr 14; 352 (15): 1519-28
49. Palmqvist M, Ibsen T, Mellen A, et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999 Jul; 160 (1): 244-9
50. Zimmerman B, D'Urzo A, Bérubé D. Efficacy and safety of formaoterol turbuhaler when added to inhaled corticosteroid treatment in children with asthma. Pediatr Pulmonol 2004; 37: 122-7
51. Russell G, Williams DA, Weller P, et al. Salmeterol xinafoate in children on high dose inhaled steroids: salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol 1995 Nov; 75 (5): 423-8
52. Tal A, Simon G, Vermeulen JH, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 2002 Nov; 34 (5): 342-50
53. Malone R, LaForce C, Nimmagadda S, et al. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Ann Allergy Asthma Immunol 2005 Jul; 95 (1): 66-71
54. Van den Berg NJ, Ossip MS, Hederos CA, et al. Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus™ inhaler (Seretide™) is effective and safe in children with asthma. Pediatr Pulmonol 2000 Aug; 30 (2): 97-105
55. Jartti TT, Kaila TJ, Tahvanainen KU, et al. Altered cardiovascular autonomic regulation after salmeterol treatment in asthmatic children. Clin Physiol 1998 Jul; 18 (4): 345-53
56. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005 Jan 15; 171 (2): 129-36
57. Finkelstein JA, Lozano P, Farber HJ, et al. Underuse of controller medications among Medicaid-insured children with asthma. Arch Pediatr Adolesc Med 2002 Jun; 156 (6): 562-7
58. Farber HJ, Capra AM, Lozano P, et al. Misunderstanding of asthma controller medications: association with nonadherence. J Asthma 2003 Feb; 40 (1): 17-25
59. Milgrom H, Bender B, Ackerson L, et al. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996 Dec; 98 (6 Pt 1): 1051-7
60. Grant EN, Malone A, Lyttle CS, et al. Asthma morbidity and treatment in the Chicago metropolitan area: one decade after national guidelines. Ann Allergy Asthma Immunol 2005 Jul; 95 (1): 19-25
61. Eshel G, Raviv R, Ben-Abraham R, et al. Inadequate asthma treatment practices and noncompliance in Israel. Pediatr Pulmonol 2002 Feb; 33 (2): 85-9
62. Farber HJ. High-quality asthma care: it's not just about drugs. Permanente J 2005; 9 (3): 32-6
63. Cochrane GM, Horne R, Chanez P. Compliance in asthma. Respir Med 1999 Nov; 93 (11): 763-9
64. Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP. Interventions for enhancing medication adherence (Cochrane Review). In: The Cochrane Library, issue 4, 2006 [online]. Available from URL: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000011/frame. html [Accessed 2006 Dec 14]
65. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004 Feb; 113 (2): 245-51
66. Stempel DA, Stoloff SW, Carranza Rosenzweig JR, et al. Adherence to asthma controller medication regimens. Respir Med 2005 Oct; 99 (10): 1263-7
67. Bosley CM, Parry DT, Cochrane GM. Patient compliance with inhaled medication: does combining beta-agonists with corticosteroids improve compliance? Eur Respir J 1994 Mar; 7 (3): 504-9
68. van Grunsven PM. The magnitude of fear of adverse effects as a reason for nonparticipation in drug treatment: a short review. J Asthma 2001 Apr; 38 (2): 113-9
69. Scarfone RJ, Capraro GA, Zorc JJ, et al. Demonstrated use of metered-dose inhalers and peak flow meters by children and adolescents with acute asthma exacerbations. Arch Pediatr Adolesc Med 2002 Apr; 156 (4): 378-83
70. Crompton GK, Barnes PJ, Broeders M, et al. The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. Respir Med. Epub 2006 Feb 20
71. Kamps AW, van Ewijk B, Roorda RJ, et al. Poor inhalation technique, even after inhalation instructions, in children with asthma. Pediatr Pulmonol 2000 Jan; 29 (1): 39-42
72. Smith DH, Malone DC, Lawson KA, et al. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997 Sep; 156 (3 Pt 1): 787-93
73. Taylor WR, Newacheck PW. Impact of childhood asthma on health. Pediatrics 1992 Nov; 90 (5): 657-62
74. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000 Oct 12; 343 (15): 1054-63
75. Gendo K, Sullivan SD, Lozano P, et al. Resource costs for asthma related care among pediatric patients in managed care. Ann Allergy Asthma Immunol 2003 Sep; 91 (3): 251-7
76. Schatz M, Zeiger RS, Vollmer WM, et al. Validation of a beta-agonist long-term asthma control scale derived from computerized pharmacy data. J Allergy Clin Immunol 2006 May; 117 (5): 995-1000
77. Lieu TA, Quesenberry CP, Sorel ME, et al. Computer-based models to identify high-risk children with asthma. Am J Respir Crit Care Med 1998 Apr; 157 (4 Pt 1): 1173-80
78. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med 2006 Jun 1; 354 (22): 2349-59
79. Crown WH, Berndt ER, Baser O, et al. Benefit plan design and prescription drug utilization among asthmatics: do patient copayments matter? Front Health Policy Res 2004; 7: 95-127
80. Lyseng-Williamson KA, Plosker GL. Inhaled salmeterol/fluticasone propionate combination a pharmacoeconomic review of its use in the management of asthma. Pharmacoeconomics 2003; 21 (13): 951-89
81. Goldsmith DR, Keating GM. Budesonide/formoterol: a review of its use in asthma. Drugs 2004; 64 (14): 1597-618
82. Brüggenjürgen B, Selim D, Kardos P, et al. Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma. Pharmacoeconomics 2005; 23 (7): 723-31
83. Borker R, Emmett A, Jhingran P, et al. Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves. Ann Allergy Asthma Immunol 2005 Aug; 95 (2): 181-9
84. O'Connor RD, Nelson H, Borker R, et al. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics 2004; 22 (12): 815-25
85. Rubin BK. What does it mean when a patient says, "my asthma medication is not working?". Chest 2004 Sep; 126 (3): 972-81
86. Johansson G, Ställberg B, Tornling G, et al. Asthma treatment preference study: a conjoint analysis of preferred drug treatments. Chest 2004 Mar; 125 (3): 916-23
87. Balsbaugh TA, Chambers CV, Diamond JJ. Asthma controller medications: what do patients want? J Asthma 1999 Oct; 36 (7): 591-6
88. Weiss KB, Paramore LC, Liljas B, et al. Patient satisfaction with budesonide Turbuhaler™ versus triamcinolone acetonide administered via pressurized metered-dose inhaler in a managed care setting. J Asthma 2005 Nov; 42 (9): 769-76
89. Welch MJ, Nelson HS, Shapiro G, et al. Comparison of patient preference and ease of teaching inhaler technique for Pulmicort Turbuhaler® versus pressurized metered-dose inhalers. J Aerosol Med 2004; 17 (2): 129-39
90. Sheth K, Bernstein JA, Lincourt WR, et al. Patient perceptions of an inhaled asthma medication administered as an inhalation powder via the Diskus or as an inhalation aerosol via a metered-dose inhaler. Ann Allergy Asthma Immunol 2003 Jul; 91 (1): 55-60
91. Caress AL, Beaver K, Luker K, et al. Involvement in treatment decisions: what do adults with asthma want and what do they get? Results of a cross sectional survey. Thorax 2005 Mar; 60 (3): 199-205
92. Wilson SR, Strub P, Buist AS, et al. Does involving patients in treatment decisions improve asthma controller medication adherence? [abstract]. ATS 2006 San Diego International Conference; 2006 May 19-24; San Diego. New York: ATS 2006 San Diego International Conference, 2006 [online]. Available from URL: http://www.abstracts2view.com/ats06/view.php?nu=ATS06L_4558&terms= [Accessed 2006 Dec 15]
93. Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care 2005 Oct; 50 (10): 1360-75
94. Kamps AW, Brand PL, Roorda RJ. Determinants of correct inhalation technique in children attending a hospital-based asthma clinic. Acta Paediatr 2002; 91 (2): 159-63
95. Interiano B, Guntupalli KK. Metered-dose inhalers: do health care providers know what to teach? Arch Intern Med 1993 Jan 11; 153 (1): 81-5
96. Jones JS, Holstege CP, Riekse R, et al. Metered-dose inhalers: do emergency health care providers know what to teach? Ann Emerg Med 1995 Sep; 26 (3): 308-11
97. Tsang KW, Lam WK, Ip M, et al. Inability of physicians to use metered-dose inhalers. J Asthma 1997; 34 (6): 493-8
98. Pedialink Learning Center. American Academy of Pediatrics. Welch MJ, Williams P, Farber HJ, et al. Asthma gadgets [online]. Available from URL: http://www.pedialink.org/cme/_coursefinder/CMEdetail.cfm?aid=24362&area= liveCME [Accessed 2006 Dec 14]
99. American College of Chest Physicians. Patient Instructions for inhaled devices [online]. Available from URL: http://www.chestnet.org/patients/guides/ inhaledDevices.php [Accessed 2006 Dec 14]
100. Glassroth J. The role of long acting beta-agonists in the management of asthma: analysis, meta-analysis, and more analysis. Ann Intern Med 2006 Jun 20; 144 (12): 936-7
101. Adams RJ, Fuhlbrigge A, Finkelstein JA, et al. Impact of inhaled antiinflammatory therapy on hospitalization and emergency department visits for children with asthma. Pediatrics 2001 Apr; 107 (4): 706-11
102. Blais L, Suissa S, Boivin JF, et al. First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma. Thorax 1998 Dec; 53 (12): 1025-9
103. drugstore.com c1995-2005 [online]. Available from URL: http://www.drugstore.com [Accessed 2006 May 10]